P6V8-3NCS-2C (SEQ ID NO:18 for Patent US 20030186868 A1)

General Information


DRACP ID  DRACP02495

Peptide Name   P6V8-3NCS-2C (SEQ ID NO:18 for Patent US 20030186868 A1)

Sequence  KGRGKRRREKQRPSDKP

Sequence Length  17

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Cancer targeted peptides Antiangiogenic Antagonists of VEGF165 signaling through



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  VEGF165

Affinity  Not available

Mechanism  Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-9, without affecting VEGF signaling through other pathways.

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02495

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C85H155N37O24

Absent amino acids  ACFHILMNTVWY

Common amino acids  R

Mass  236494

Pl  12.36

Basic residues  9

Acidic residues  2

Hydrophobic residues  0

Net charge  7

Boman Index  -11939

Hydrophobicity  -314.12

Aliphatic Index  0

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 20030186868 A1

Patent Title  Anti-angiogenic peptides

Other Iinformation  Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status: Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006

Other Published ID  AU2002340080A1  US7052705B2  WO03029275A2  WO03029275A3 




DRACP is developed by Dr.Zheng's team.